Search Bar & Filters
Found 48 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.
Actively Recruiting
Researchers are conducting a multicenter, nonrandomized, open-label Phase III clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ICP-723 in patients with solid tumors. The study focuses on patients with surgically unresectable locally advanced or metastatic solid tumors, including primary central nervous system tumors. This trial aims to better understand how ICP-723 behaves in the body and its safety profile during treatment. Participants will receive ICP-723, a white, round, uncoated tablet, as the investigational drug. The study includes adolescent participants aged 12 to under 18 years and adults aged 18 years and older. The trial involves monitoring treatment-emergent adverse events for up to 12 months and determining the maximum tolerated dose within the first two months. Secondary measures include peak drug concentration and objective response rate within specified time frames. During the study, participants will undergo evaluations of safety and tolerability, including assessments of adverse events and pharmacokinetic measurements. Measurable tumor lesions will be monitored according to established criteria. Patients will need to agree to use effective birth control methods if of childbearing potential and comply with visit schedules and treatment regimens. The total participation period includes follow-up for safety and treatment response, with data collected up to 12 months.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
Researchers are evaluating the safety, feasibility, and early antitumor activity of a combination treatment using an intratumoral oncolytic virus H101 and immune checkpoint inhibitors ICIs in patients with advanced metastatic colorectal cancer, gastric cancer, or hepatocellular carcinoma who have not responded to multiple prior therapies. This single-arm, open-label study also aims to explore how this combination changes the tumors immune environment and to identify potential biomarkers predicting treatment response. Participants receive intratumoral injections of H101 once every 2-3 weeks for four cycles, with the dose based on tumor size. Five to seven days after each H101 injection, they are given intravenous ICIs, either anti-PD-1 alone or combined with anti-CTLA-4 antibodies, according to the physicians choice. Tumor biopsies and blood samples are collected before starting treatment and after the final cycle to analyze immune changes and biomarkers. During the study, participants undergo regular clinical assessments, tumor imaging to evaluate response, and safety monitoring for adverse events. Adverse events are graded using standard criteria from the first dose until 30 days after treatment ends. Tumor responses are measured by established criteria, and progression-free survival is tracked for up to two years. All data are securely managed, and the study follows ethical guidelines with informed consent from all patients.
Actively Recruiting
Researchers are investigating the use of intratumoral H101 oncolytic virus combined with immune checkpoint inhibitors ICIs in patients with advanced Stage IV breast cancer who have not responded to multiple prior treatments. This prospective, single-center, open-label, real-world observational study aims to preliminarily assess the antitumor activity, safety, and changes in the tumor immune microenvironment caused by this combination therapy in 10 to 15 patients aged 18 to 75 years with measurable and injectable lesions. The treatment framework includes 2- to 3-week cycles for a total of 4 planned cycles. On day 1 of each cycle, H101 is injected directly into tumors, with the dose adjusted by lesion size. ICIs, including anti-PD-1 and optionally anti-CTLA-4 antibodies, are infused intravenously 7 2 days after the H101 injection. The exact regimen is decided by physicians based on individual patient status and multidisciplinary advice. Tumor biopsies and blood samples are collected before treatment and after 4 cycles to analyze immune cell changes and gene expression. Participants undergo regular assessments including radiographic evaluations starting 6-8 weeks after treatment completion and every 3 months thereafter for up to one year or until disease progression. Safety is monitored through adverse event reporting using standardized criteria. Researchers measure outcomes such as objective tumor response, local lesion control, disease control rate, progression-free survival, and immune environment changes. The study includes comprehensive follow-up and data protection to ensure participant safety and scientific rigor.
Actively Recruiting
Researchers are conducting a Phase III international clinical trial to assess the safety and effectiveness of furmonertinib combined with platinum-based doublet chemotherapy versus osimertinib alone in patients with non-squamous non-small cell lung cancer NSCLC that has an EGFR sensitizing mutation and brain metastases. The study also includes a group receiving furmonertinib alone to further explore its effects. This trial aims to understand better treatment options for this specific lung cancer subgroup. The study has two stages. The first stage focuses on safety and involves about 30 participants receiving either 80 mg or 160 mg of furmonertinib daily combined with chemotherapy to evaluate tolerability. The second stage randomizes around 350 participants into three groups furmonertinib with chemotherapy, osimertinib alone, or furmonertinib alone. Treatments are given in cycles of 21 days and continue until unacceptable side effects, disease progression, death, or new treatment begins. Chemotherapy includes drugs like carboplatin, cisplatin, and pemetrexed administered intravenously every three weeks for up to four cycles. Participants will undergo regular assessments including monitoring of side effects, disease progression, and survival for up to four years. Researchers will use imaging and clinical evaluations to measure outcomes such as progression-free survival and response rates. Patient-reported outcomes and various blood tests will also be collected. Safety monitoring involves tracking adverse events and serious adverse events throughout the study duration. The total study period extends until September 2029, with detailed follow-up to observe long-term effects and treatment impact.
Actively Recruiting
Researchers are evaluating the safety and tolerability of the drug BL-M07D1 in patients with locally advanced or metastatic HER2-positive or low-expression breast cancer and other solid tumors. This study aims to determine the dose-limiting toxicity and maximum tolerated dose in an initial phase Ia, and then further assess safety to recommend a dose for future phase II studies during phase Ib. It also explores preliminary effectiveness, how the drug behaves in the body, and its immune response. Participants receive BL-M07D1 by intravenous infusion during the first treatment cycle lasting three weeks. Those who benefit can continue receiving additional cycles until the disease progresses, intolerable side effects occur, or other reasons for stopping arise. The study consists of a single group receiving the investigational drug without a placebo or comparison treatment. During the study, participants undergo safety monitoring for adverse events and evaluations of drug levels in the body for up to 21 days after the first dose. The research team measures outcomes such as dose-limiting toxicities, maximum tolerated dose, recommended dose for phase II, and treatment-emergent adverse events for up to about 24 months. Other assessments include anti-drug antibodies, tumor response rates, duration of response, and progression-free survival. Participants are monitored closely throughout their involvement, which can last up to approximately two years.
Actively Recruiting
Researchers are evaluating HLX42, an investigational anti-EGFR antibody drug conjugate, in patients with advanced or metastatic solid tumors including non-small cell lung cancer NSCLC. This open-label, first-in-human phase I study aims to assess the safety and tolerability of HLX42, focusing on dose-limiting toxicities and maximum tolerated dose. The study includes patients whose tumors are resistant or intolerant to standard treatments or for whom no standard therapy exists. The trial has two stages initially, a dose escalation phase using a 33 design where patients receive escalating doses of HLX42 via intravenous infusion and are monitored for toxicities during the first 3 weeks. In the second stage, about 60 patients are randomized into two groups receiving fixed doses of HLX42 at 2.5 mgkg or 2.0 mgkg every three weeks. Treatment continues until disease progression, intolerable side effects, or patient withdrawal. Participants will undergo regular assessments including tumor measurements by RECIST 1.1 criteria, laboratory tests, and evaluations of organ function. Safety is closely monitored through adverse event recording up to 90 days after the last dose. The study will also evaluate pharmacokinetic characteristics and anti-drug antibodies over approximately 24 months, with survival outcomes tracked during this period. Treatment tolerability and clinical benefit guide ongoing therapy decisions throughout the trial.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of olverembatinib combined with chemotherapy compared to an investigators choice of tyrosine kinase inhibitor TKI combined with chemotherapy in adults newly diagnosed with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Ph ALL. This global, randomized, open-label Phase 3 study aims to provide important information about treatment options for this specific type of leukemia. Participants will receive either olverembatinib taken orally every other day along with chemotherapy, or a TKI chosen by the investigator taken orally once daily with chemotherapy. The study includes two groups one receiving the experimental olverembatinib combination and the other receiving the control treatment with investigator-selected TKI. Treatment cycles last 28 days, and the study follows participants through multiple cycles. During the study, participants will be monitored for their response to treatment by checking minimal residual disease negative complete remission rates during the first three cycles. Researchers will also assess event-free survival for up to 3 to 6 years, treatment-related side effects, drug levels in the blood, and quality of life related to leukemia. Safety assessments and other evaluations will continue through approximately two years of study participation, allowing for long-term monitoring of treatment effects and participant health.
1-10 of 48
1